The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

PBC is a rare, autoimmune, cholestatic liver disease with genetic and environmental pathogenetic factors. Data about epidemiology of PBC in Switzerland are completely lacking. Epidemiology can be a powerful tool in yielding important clues as to burden and etiology of diseases. In addition, the investigators study will be the first one carried out in the country on PBC, and therefore will raise disease awareness and create a network.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Primary Biliary Cirrhosis Bile Duct Diseases Biliary Tract Diseases Cholestasis Cholestasis, Intrahepatic Digestive System Diseases Fibrosis Liver Cirrhosis Liver Cirrhosis, Biliary Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondazione Epatocentro Ticino

Lugano, 6900, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

PBC patients living in Switzerland

Exclusion criteria

Treatment and study plan

Primary outcomes

Prevalence of PBC in Switzerland

Time frame: from 1.1.2005 until 31.12.2015

Sponsors and collaborators

Lead sponsor

Fondazione Epatocentro Ticino

Other

Collaborators

Intercept Pharmaceuticals
Vifor Pharma

Registry information

Important dates

Study start: 2015
Primary completion: 2016
Study completion: 2017
First posted: Jul 27, 2016
Registry last updated: Aug 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed